OpenAI cut standard API prices for GPT-5.6 Luna by 80 percent and Terra by 20 percent on July 30, 2026, while leaving Sol unchanged. The company credited lower serving costs and better token-generation efficiency; Chinese vendors are also expanding lower-cost and open-weight alternatives.
VA Providence began rolling out an ambient AI scribe in primary care on March 24, 2026, with participation optional for veterans. The software turns clinical conversations into draft notes, leaving accuracy, consent and liability subject to rules that vary by country.
NVIDIA's August 6, 2026, configuration guide separates AI training and inference systems and says hardware choices vary by workload. A buyer still needs a controlled run of its own model, software and traffic because peak chip specifications do not measure end-to-end service or three-year cost.
The 2019 Apple Heart Study sent irregular-pulse notifications to 0.52 percent of 419,297 participants, while later ECG patches found atrial fibrillation in 34 percent of 450 analyzable recipients. Its 84 percent positive predictive value measured a different event: another alert that occurred during simultaneous ECG recording.
China's internet regulator registered Apple Intelligence for use on iPhones on July 15, 2026, clearing a major barrier to its release in mainland China. The service will draw on AI models from Alibaba and Baidu, but Apple has not announced a launch date.
National Taiwan University Hospital said in 2026 that it had built a federated-learning platform with partner hospitals to validate medical AI without moving their data off site. The approach limits centralized data collection, but it does not eliminate privacy, performance or accountability risks.
The US Food and Drug Administration cleared AEYE-DS for use with the handheld Optomed Aurora retinal camera on April 23, 2024. The system automatically returns a screening result, but its authorization and performance data have defined limits.
Taiwan added 17 smart assistive products to a long-term-care rental benefit on July 1, 2026. The published list identifies products and suppliers but does not provide performance metrics or explain how each system makes decisions.
OpenAI began rolling out Health in ChatGPT to US adults on July 23, 2026, with connections to Apple Health and supported medical records. Taiwan's My Health Bank SDK instead sends selected records to third-party apps after a government review, and new SDK applications are currently paused.
A September 2025 paper argued that language-model training and widely used benchmarks reward guessing over acknowledging uncertainty. A 2026 health-chatbot audit found 49.6 percent of answers problematic, showing how fluent errors can reach high-stakes uses.
AI-designed drug candidates have moved into mid- and late-stage trials, but APPI News found no publicly identified US approval for a novel drug originating from an AI-led discovery program as of August 4, 2026. Early data point to faster candidate selection and stronger Phase 1 results, while later trials still impose the usual tests of safety and efficacy.
Taiwan-listed Bionime secured a local medical-device license for its iFree2 continuous glucose monitor in April 2026, but the public notice did not identify an AI forecasting feature. Abbott's Libre Assist offers such predictions in the United States, while Abbott's Taiwan product site lists an older sensor and does not advertise the feature.
Taiwan's health insurance agency said in August 2024 that it aimed to finish a cost-effectiveness review of AI diagnostic tools by the end of that year. APPI News could not find a published payment decision for the proposed CT brain-scan application as of August 3, 2026.
The US Food and Drug Administration cleared UpDoc on December 23, 2025, as prescription software for adults with type 2 diabetes. Its chat interface collects patient data, while insulin instructions follow clinician-set treatment parameters.
Taiwan's health ministry says three hospital groups completed a cross-system FHIR demonstration by the end of 2025. The standard can make records easier for software and AI tools to query, but it does not settle data quality, access control or accountability.
The World Health Organization and the International Telecommunication Union mapped the use of AI in traditional medicine in a 2025 technical brief. Their findings, combined with international medical-software standards, show why a product demonstration cannot establish clinical credibility.
GPT-5 Pro generated a mechanism for unexplained T-cell data and predicted the direction of an unpublished CAR-T experiment, according to a November 2025 case study. The result shows how a model can help experts form testable hypotheses, but it does not establish autonomous discovery or prove the proposed mechanism.
OpenAI and Molecule.one reported on June 17 that a GPT-5.4 workflow helped identify conditions that improved a difficult Chan-Lam coupling across 10,080 microscale reactions. An automated laboratory supplied the testing capacity, while chemists selected proposals, corrected plans and repeated key experiments by hand.
OpenAI reported in June 2026 that GPT-Rosalind passed 36.1 percent of the 750 tasks in its new LifeSciBench evaluation. Performance fell on tasks involving figures, files or web sources, while the benchmark's design and publication by OpenAI complicate interpretation of its model rankings.
